The Use of Rad51 Promoter Constructs in Anticancer Therapy

Brief Description

Applications:

This technology provides a potential method for the killing or at least inhibiting cell growth of only cancer cells, by the induction of cytotoxic genes using Rad51 promoter constructs. The Rad51 promoters can also be used as an indicator marker for cancer cells to aid in diagnosis and possible treatments.

Advantages:

The advantage of this method over other anticancer therapies is that it allows the selective killing of cancer cells with potentially no toxicity to normal cells. This is because cancer cells display an overexpression of the Rad51 protein, so the Rad51 promoter activity is 20-1000 fold higher in cancer cells, while in normal human fibroblast cells it is highly repressed.

Patent Information:
Title Country Patent No. Issued Date
RAD51-Derived Cancer Cell-Specific Promoters for Targeted Anti-Cancer Therapy United States 8,188,252 5/29/2012
Category(s):
Therapeutic
For Information, Contact:
Matan Rapoport
Licensing Associate
University of Rochester
585.276.6600
matan.rapoport@rochester.edu
Inventors:
Vera Gorbunova
Andrei Seluanov
Christopher Hine
Keywords:
Cancer
Therapy